Here, I’ll talk about our Randomized Controlled Trial to examine the effects of Plasmalogen on patients with mild Alzheimer’s disease and Mild Cognitive Impairment.
Here is our study design. 328 patients, aged 60-85 years. They were randomized to receive either 1mg/day plasmalogens or placebo for 24 weeks. We assessed the safety to these patients by monthly clinic visit. Of 328 patients enrolled, 276 patients completed the 24- week follow-up.
Here is a breakdown of the study participants. Number of cases was 178 in Mild Cognitive Impairment, 98 in mild Alzheimer’s Disease.
The sub-analysis by sex and age in patients with mild Alzheimer’s Disease. Closed circle indicates Plasmalogen group, and open circle does placebo group, respectively. In female subjects, WMS-R, the marker of memory function, improved significantly in Plasmalogen group and there were significant differences between Plasmalogen and placebo groups as shown in the left panel. Right panel indicates the difference by age. In 77 or younger group, WMS-R significantly improved in Plasmalogen group and showed the significant differences between Plasmalogen and placebo groups.